Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 44-53 , January 2008

Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States

  • Joshua S. Benner, PharmD, ScD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
    • Corresponding Author InformationCorresponding author: Joshua S. Benner, PharmD, ScD, Principal, IMS Health, Inc., 300 N. Washington Street, Suite 303, Arlington, Virginia 22046. Tel: 703-286-2868; fax: 703-286-2899.
    • ,
  • Timothy W. Smith, BA

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
    • ,
  • Allison A. Petrilla, MPH

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Ms. Petrilla and Ms. Goel are consultants to IMS Health, Inc, and Ms. Petrilla is a former employee of IMS Health, Inc.
    • ,
  • David Klingman, PhD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Drs. Benner, Smith, and Klingman are all employees of IMS Health, Inc, a health information services and consulting firm. They have provided consulting services to manufacturers of antihypertensive and lipid-lowering therapies, including Pfizer Inc., Schering-Plough Corporation, and AstraZeneca Pharmaceuticals LP.
    • ,
  • Sangeeta Goel, PharmD

      Affiliations

    • IMS Health, Inc., Arlington, Virginia, USA
    • Ms. Petrilla and Ms. Goel are consultants to IMS Health, Inc, and Ms. Petrilla is a former employee of IMS Health, Inc.
    • ,
  • Simon S.K. Tang, MPH

      Affiliations

    • Pfizer Inc., New York, New York, USA
    • Mr. Tang is an employee of, and holds stock options for, Pfizer Inc.
    • ,
  • Nathan D. Wong, PhD

      Affiliations

    • Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, California, USA
    • Dr. Wong receives grant support from Pfizer Inc., and Bristol Myers Squibb, and is on the speakers’ bureau for Pfizer Inc., Sanofi-Aventis, and Takeda. The staff of IMS Health were paid consultants to Pfizer Inc., in connection with the development of this article.

Received 10 April 2007 ,Accepted 10 July 2007.

References 

  1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics––2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [Erratum in: Circulation 2007;115:e172]. Circulation. 2007;115:e69–e171
  2. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891–897
  3. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199–206
  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  5. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003;107:2185–2189
  6. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423–1426
  7. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  8. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–2031
  9. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44:720–732
  10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  11. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158
  12. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data NHANES (1999–2000) (National Center for Health Statistics (NCHS), Department of Health and Human Services). http://www.cdc.gov/nchs/about/major/nhanes/nhanes99_00.htmAccessed Date: January 13, 2005
  13. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Data NHANES (2001–2002) (National Center for Health Statistics (NCHS), Department of Health and Human Services). http://www.cdc.gov/nchs/about/major/nhanes/nhanes01-02.htmAccessed Date: January 13, 2005
  14. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Analytic Guidelines (National Center for Health Statistics (NCHS), Department of Health and Human Services). http://www.cdc.gov/nchs/data/nhanes/nhanes_general_guidelines_june_04.pdfAccessed Date: January 13, 2005
  15. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J. 2000;139:272–281
  16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  17. Wong ND, Pio JR, Franklin SS, L’Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol. 2003;91:1421–1426
  18. Wong ND, Thakral G, Franklin SS, L’Italien GJ, Jacobs MJ, Whyte JL, et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am Heart J. 2003;145:888–895
  19. Russell MW, Huse DM, Drowns S, Hamel EC, Hartz SC. Direct medical costs of coronary artery disease in the United States. Am J Cardiol. 1998;81:1110–1115
  20. US Department of Labor Bureau of Labor Statistics. Consumer Price Index – All Urban Consumers – Medical Care. www.bls.gov/cpi/home.htmAccessed Date: October 26, 2005
  21. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440–1445

 This study was supported by a Grant from Pfizer, Inc.

PII: S1933-1711(07)00158-1

doi: 10.1016/j.jash.2007.07.001

Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 44-53 , January 2008

Article Tools

* Image Usage & Resolution